CXCR4 EXPRESSION IN DIFFERENT SUBSETS OF CTCs AND SINGLE (DETACHED) BREAST CANCER CELLS
O. E. Savelieva,
L. A. Tashireva,
M. A. Buldakov,
R. H. Mukhamedzhanov,
E. V. Kaigorodova,
E. V. Denisov,
M. V. Zavyalova,
V. M. Perelmuter https://doi.org/10.21294/1814-4861-2018-17-4-75-80
Abstract
The aim of this study was to assess CXCR4 expression in different subsets of CTCs and single (detached) breast cancer cells.
Materials and methods. Thirty five patients with invasive breast carcinoma of no special
type (IC NST) (T1-4N0-2M0), between 29 and 69 years of age were included in this study. Different subsets of CTCs with CXCR4 expression were evaluated by flow cytometry. A confocal microscopy was used to assess CXCR4 expression in different subsets of single (detached) cancer cells in breast tissue.
Results. The CXCR4 was expressed in CTCs without stem-like and EMT phenotype, in CTCs with EMT but not stem markers and in stem-like CTCs without EMT features. In all blood samples, the CXCR4 expression in CTCs with stem-like and EMT phenotype was absent. In breast tumor the CXCR4 was expressed in the non stemlike single (detached) breast cancer cells with EMT features, in the single (detached) breast cancer cells with stem and EMT features. In all tumor samples the stem-like or non stem-like single (detached) breast cancer cells without EMT features were absent.
Conclusions. Different subsets of the CTCs exhibited CXCR4. The CXCR4 expression did not depend on the presence or absence of stem or/and EMT features in tumor cells. We showed that some subsets of single (detached) breast cancer cells in the primary tumor were characterized by the ability to express CXCR4 and may be a source of the respective CTC subsets.
About the Authors
O. E. Savelieva
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Tomsk State University
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
36, Lenin Ave., 634050-Tomsk, Russia
MD, DSc, Leading Researcher, Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University
Researcher ID (WOS): A-6690-2014. Author ID (Scopus): 14065805800
L. A. Tashireva
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
PhD, Senior Researcher, Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Researcher ID (WOS): C-8222-2012. Author ID (Scopus): 55234960400
M. A. Buldakov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Tomsk State University
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
36, Lenin Ave., 634050-Tomsk, Russia
PhD, Senior Researcher, Laboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University
Researcher ID (WOS): C-7922-2012. Author ID (Scopus): 55932165800
R. H. Mukhamedzhanov
Siberian State Medical University
Russian Federation
Russian Federation
2, Moskovsky trakt, 634050-Tomsk, Russia
Postgraduate, Department of Pathological Anatomy, Siberian State Medical University
E. V. Kaigorodova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Siberian State Medical University
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
2, Moskovsky trakt, 634050-Tomsk, Russia
MD, DSc, Leading Researcher, Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University
Researcher ID (WOS): A-5400-2014. Author ID (Scopus): 24778286000
E. V. Denisov
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Tomsk State University
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
36, Lenin Ave., 634050-Tomsk, Russia
PhD, Senior Researcher, Laboratory of Molecular Oncology and Immunology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University
Researcher ID (WOS): C-8662-2012. Author ID (Scopus): 26653961800
M. V. Zavyalova
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Tomsk State University
Siberian State Medical University
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
36, Lenin Ave., 634050-Tomsk, Russia
2, Moskovsky trakt, 634050-Tomsk, Russia
MD, DSc, Professor, Head of Department of Pathological Anatomy, Siberian State Medical University; Leading Researcher, Department of General and Molecular Pathology, Tomsk National Research Medical Center, Russian Academy of Sciences; Tomsk State University
Researcher ID (WOS): C-8580-2012. Author ID (Scopus): 36711031100
V. M. Perelmuter
Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
5, Kooperativny Str., 634009-Tomsk, Russia
MD, DSc, Professor, Head of Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Author ID (Scopus): 8091317300
References
1. Fidler I.J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003; 3(6): 453–8. doi: 10.1038/nrc1098.
2. Mego M., Cholujova D., Minarik G., Sedlackova T., Gronesova P., Karaba M., Benca J., Cingelova S., Cierna Z., Manasova D., Pindak D., Sufliarsky J., Cristofanilli M., Reuben J.M., Mardiak J. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer. BMC Cancer. 2016 Feb 19; 16: 127. doi: 10.1186/s12885-016-2143-2.
3. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., Bedrosian I., Kuerer H.M., Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012; 13(7): 688–95. doi: 10.1016/S1470-2045(12)70209-7.
4. Zhang L., Riethdorf S., Wu G., Wang T., Yang K., Peng G., Liu J., Pantel K. Meta- analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res. 2012 Oct 15; 18(20): 5701–10. doi: 10.1158/1078-0432.CCR-12-1587.
5. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2: 563–72. doi: 10.1038/nrc865.
6. Sarvaiya P.J., Guo D., Ulasov I., Gabikian P., Lesniak M.S. Chemokines in tumor progression and metastasis. Oncotarget. 2013; 4: 2171–85. doi: 10.18632/oncotarget.1426.
7. Raman D., Baugher P.J., Thu Y.M., Richmond A. Role of chemokines in tumor growth. Cancer Lett. 2007; 256(2): 137–65. doi: 10.1016/j.canlet.2007.05.013.
8. Kaigorodova E.V., Savelieva O.E., Tashireva L.A., Tarabanovskaya N.A., Simolina E.I., Denisov E.V., Slonimskaya E.M., Choynzonov E.L., Perelmuter V.M. Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer. Molecules. 2018 Mar 22; 23(4). pii: E727. doi: 10.3390/molecules23040727.
9. Lakhani S.R., Ellis I.O., Schnitt S.J., Tan P.H., van de Vijver M.J. World Health Organization (WHO) classification of tumours of the breast. Lyon, France: IARC Press, 2012. 240.
10. Hinton C.V., Avraham S., Avraham H.K. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 2010 Feb; 27(2): 97–105. doi: 10.1007/s10585-008-9210-2.
11. Xu Ch., Zhao H., Chen H., Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Design, Development and Therapy. 2015; 9: 4953–64. doi: 10.2147/DDDT.S84932.
Review
For citations:
Savelieva O.E., Tashireva L.A., Buldakov M.A., Mukhamedzhanov R.H., Kaigorodova E.V., Denisov E.V., Zavyalova M.V., Perelmuter V.M. CXCR4 EXPRESSION IN DIFFERENT SUBSETS OF CTCs AND SINGLE (DETACHED) BREAST CANCER CELLS. Siberian journal of oncology. 2018;17(4):75-80. https://doi.org/10.21294/1814-4861-2018-17-4-75-80
Views:
931
Email this article 
